Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Market Report Overview

IPF is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). ILDs are characterized by damage to the lung parenchyma (the functional part of the lung that includes the alveolar tissue, bronchioles, bronchi, blood vessels, and interstitium) that occurs as a consequence of aberrant inflammation and fibrosis, thickening and scarring of the connective tissue. The development and progression of fibrosis in IPF patients is extremely heterogeneous.

The Idiopathic Pulmonary Fibrosis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for idiopathic pulmonary fibrosis (IPF). The report also analyzes the clinical and commercial landscapes of IPF, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Idiopathic Pulmonary Fibrosis Marketed Drugs Segmentation by Mechanism of Action

The key mechanisms of action for IPF marketed drugs are receptor agonist, enzyme inhibitor, and receptor inhibitor. Out of all available marketed products used for IPF (including generics and products used for symptomatic treatment), the majority are receptor agonists.

Idiopathic Pulmonary Fibrosis Marketed Drugs Analysis, by Mechanism of Action, 2023 (%)

For more MoA insights into IPF marketed drugs, download a free report sample

IPF Marketed Drugs Segmentation by Routes of Administration

The key routes of administration for IPF marketed drugs are oral, topical, injection, and inhalational. Most marketed drugs for IPF are administered through the oral route, followed by injection.

Idiopathic Pulmonary Fibrosis Marketed Drugs Analysis by RoA, 2023 (%)

For more RoA insights into the IPF marketed drugs, download a free report sample

Idiopathic Pulmonary Fibrosis Pipeline Drugs Segmentation by Mechanisms of Action

The key mechanisms of action for IPF pipeline drugs are enzyme inhibitor, receptor antagonist, protein and peptide inhibitor, receptor agonist, biological factor inhibitor, receptor inhibitor, enzyme activator, ion channel blocker, protein and peptide activator, genes, nucleic acids & related components activator, genes, nucleic acids & related components inhibitor, ligand scavenger, ion channel activator, and biological factor activator. Most of the IPF pipeline drugs are enzyme inhibitors.

Idiopathic Pulmonary Fibrosis Pipeline Drugs Analysis by MoA, 2023 (%)

For more MoA insights into the IPF pipeline drugs market, download a free report sample

IPF Pipeline Drugs Segmentation by Routes of Administration

The key routes of administration for IPF pipeline drugs are oral, injection, inhalational, and topical. The pipeline drugs for IPF are mostly oral therapies, followed by injection.

Idiopathic Pulmonary Fibrosis Pipeline Drugs Analysis by RoA, 2023 (%)

For more RoA insights into the IPF pipeline drugs market, download a free report sample

Idiopathic Pulmonary Fibrosis Pipeline Drugs Segmentation by Molecule Type

Most of the pipeline drugs for IPF are small molecules. Biologic and oligonucleotide are the other significant molecule types in the pipeline drugs for IPF.

Idiopathic Pulmonary Fibrosis Pipeline Drugs Analysis by Molecule Types, 2023 (%)

For more molecule type insights into the IPF pipeline drugs market, download a free report sample

Top Sponsors in the IPF Marketed and Pipeline Drugs Market

Some of the top sponsors in the IPF marketed and pipeline drugs market are Boehringer Ingelheim International GmbH, Galapagos NV, Bristol- Myers Squibb Co, F.Hoffmann-La Roche Ltd, Vicore Pharma AB, Celgene Corp, Pliant Therapeutics Inc, Sunshine Lake Pharma Co Ltd, Afferent Pharmaceuticals, and Daewoong Pharmaceuticals Inc. Among the key players, Santen Pharmaceutical has been sponsoring the highest number of Phase III trials.

Idiopathic Pulmonary Fibrosis Marketed Drugs Report Overview

Idiopathic Pulmonary Fibrosis Pipeline Drugs Market Report Overview

Segments Covered in the Report

IPF Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)

• Receptor Agonist
• Enzyme Inhibitor
• Receptor Inhibitor

IPF Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)

• Oral
• Topical
• Injection
• Inhalational

IPF Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)

• Enzyme Inhibitor
• Receptor Antagonist
• Protein and Peptide Inhibitor
• Receptor Agonist
• Biological Factor Inhibitor
• Receptor Inhibitor
• Enzyme Activator
• Ion Channel Blocker
• Protein and Peptide Activator
• Genes, Nucleic Acids & Related Components Activator
• Genes, Nucleic Acids & Related Components Inhibitor
• Ligand Scavenger
• Ion Channel Activator
• Biological Factor Activator

IPF Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)

• Oral
• Injection
• Inhalational
• Topical

IPF Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)

• Small Molecule
• Biologic
• Oligonucleotide

Scope

GlobalData’s IPF: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the report include –

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the IPF market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.